Sponge Sampling with Fluorescent In Situ Hybridization as a Screening Tool for the Early Detection of Esophageal Cancer

Haisley, Kelly R.; Dolan, James P.; Olson, Susan B.; Toledo-Valdovinos, Sergio A.; Hart, Kyle D.; Bakis, Gene; Enestvedt, Brintha K.; Hunter, John G.

doi:10.1007/s11605-016-3239-3

Cited by 14 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on our data, the proportion of abnormal cells was very small, and manual screening for few cells of interest among all available cells is very challenging. Thus, some other examinations, such as immunochemical staining of trefoil factor3 12 and p53, 11 as well as fluorescent in-situ hybridization of p53, 14 were applied as alternative methods for evaluation of Cytosponge derived specimens. Although a batch strategy can be applied for laboratory treatment, it is time-consuming to evaluate all prepared slides by manual diagnosis.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A Rapid Cytological Screening as pre-Endoscopy Screening for Early Esophageal Squamous Cell Lesions: A Prospective Pilot Study from a Chinese Academic Center

Feng

Liu

Yao³

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Background: Cytological detection of early esophageal squamous cell carcinoma (ESCC) remains challenging. Therefore, we introduced a rapid cytological screening method and evaluated its efficacy as a pre-endoscopy screening for early ESCC and precursor lesions. Methods: This method consisted of a sponge sample retrieval, automatic liquid-based cytological treatment and slides preparation, computer-assisted screening and manual diagnosis. Efficacy for detection of early ESCC and precursor lesions was evaluated. Also, diagnostic efficiency was compared with manual diagnosis. Results: Eighty-three patients with early ESCC and precursor lesions and 2,090 asymptomatic participants with high risks of ESCC were enrolled. Whole procedure was accomplished within two working days. Abnormal cells were detected in all 83 patients, and in 272 (13.01%) subjects among 2,090 asymptomatic participants. Early ESCC, high-grade intraepithelial neoplasia, low-grade intraepithelial neoplasia and reflux esophagitis and normal endoscopic findings were detected in 8, 13, 11, 187 and 53 participants with abnormal cells, respectively. The calculated sensitivity, specificity, positive predictive value and negative predictive value for detection of early ESCC and precursor lesions were 100%, 88.34%, 11.76%, and 100%, respectively. Compared with manual diagnosis, this method was accomplished in a shorter time duration (5.4 ± 0.45 min vs 320.2 ± 132.4 min, p < 0.001), a higher diagnostic accuracy (96.7% vs74.4%, p = 0.015) and a better inter-observer agreement (93.3% vs66.7%, K = 0.286, p < 0.001). Conclusions: Our study provides a promising methodology as pre-endoscopy screening for early ESCC and precursor lesions.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The present specificity and PPV are similar with those from previous studies by performing immunochemical staining and FISH targeting p53. 11 , 14 By using this threshold, the numbers of participants who need endoscopy was significantly limited. Therefore, this method can make large-scale endoscopy screening much cost-saving.…”

Section: Discussionmentioning

confidence: 99%

A Rapid Cytological Screening as pre-Endoscopy Screening for Early Esophageal Squamous Cell Lesions: A Prospective Pilot Study from a Chinese Academic Center

Feng

Liu

Yao³

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Renal function was significantly restored, and the FISH test was negative again. Studies [ 68 , 69 , 70 , 71 ] have shown that the tumor cells of esophageal squamous cell carcinoma and non-Hodgkin’s lymphoma have the possibility of aberrations on chromosomes 3, 7 and 17 or (and) deletion of the p21 gene locus on chromosome 9. Urinary FISH may be positive if tumor cells metastasize to the kidney and invade the renal parenchyma and collecting system, and can shed a sufficient amount into the urine.…”

Section: Analysis Of the Characteristics Of Urinary Fish-positive Cas...mentioning

confidence: 99%

UroVysionTM Fluorescence In Situ Hybridization in Urological Cancers: A Narrative Review and Future Perspectives

Yang

2022

Cancers

View full text Add to dashboard Cite

UroVysionTM is a fluorescence in situ hybridization assay that was developed for the detection of bladder cancer (UC accounted for 90%) in urine specimens. It consists of fluorescently labeled DNA probes to the pericentromeric regions of chromosomes 3, 7, 17 and to the 9p21 band location of the P16 tumor suppressor gene, which was approved by the Food and Drug Administration (FDA) in 2001 and 2005, respectively, for urine detection in patients with suspected bladder cancer and postoperative recurrence monitoring. Furthermore, recent studies also demonstrated that U-FISH was useful for assessing superficial bladder cancer patients’ response to Bacillus Calmette–Guérin therapy and in detecting upper tract urothelial carcinoma. Therefore, positive U-FISH was well known to urologists as a molecular cytogenetic technique for the detection of UC. However, with the continuous enrichment of clinical studies at home and abroad, U-FISH has shown a broader application space in the detection of various urinary primary tumors and even metastatic tumors. This review focuses on summarizing the research status of U-FISH in UC, non-urothelial carcinoma and metastatic tumor, so as to strengthen urologists’ more comprehensive understanding of the application value of U-FISH and better complete the accurate diagnosis and treatment of urological cancers.

show abstract

“…Screening mit nichtendoskopischer Abrasiv-Zytologie (Cytosponge etc.) in Kombination mit Biomarkern Die Anwendung nichtendoskopischer Abrasiv-Zytologie ist ein in Asien und Europa seit langem praktiziertes Verfahren im Screening auf Plattenepithelkarzinome des Ösophagus [50][51][52][53]. Die Verwendung der Abrasiv-Zytologie als Screening-Verfahren auf BE und EAC ist dagegen eine relativ neue Methode (▶ Abb.…”

Section: Erweiterte Auswertung Von Biopsien Auf Biomarker Für Intraepunclassified

Barrett-Screening: rationale, aktuelle Konzepte und Perspektiven

et al. 2020

View full text Add to dashboard Cite

ZusammenfassungDer Barrett-Ösophagus (BE) stellt den wichtigsten Risikofaktor für das ösophageale Adenokarzinom dar. Derzeit ist kein hinreichend effizientes Screening-Programm verfügbar, um in der Gesamtpopulation Patienten mit einem hohen Risiko für ein ösophageales Adenokarzinom auf dem Boden eines Barrett-Ösophagus zu identifizieren. Das aktuelle endoskopische Screening zielt auf symptomatische Refluxpatienten, aus denen sich aber nur ein Teil der Risikopatienten rekrutiert. Derzeit werden verschiedene neue Verfahren untersucht, die die Effektivität des Screenings deutlich erhöhen könnten.Selektive Literaturrecherche in MEDLINE/PubMed unter Berücksichtigung deutscher und internationaler Leitlinien.Alternative Screening-Verfahren könnten 2-stufig angelegt sein: Zunächst die Identifikation von Personen „at risk“ über eine Erfassung geeigneter biologischer Marker, dann deren gezielte endoskopisch-bioptische Abklärung, Risikostratifikation, Überwachung (Surveillance) und ggf. Therapie. Neue diagnostische Methoden wie der Cytosponge® in Kombination mit einer Auswertung von Markern für Barrett-Schleimhaut könnten einen wesentlichen Fortschritt darstellen.Barrett-Karzinome zeigen nach wie vor eine zunehmende Inzidenz und eine (trotz therapeutischer Fortschritte) ungünstige Prognose, wobei aber Patienten mit Barrett-Frühkarzinomen eine gute Prognose hinsichtlich Langzeitüberleben aufweisen. Eine verbesserte Früherkennung ist dringend wünschenswert, da bisher die meisten Patienten erst im fortgeschrittenen Stadium endoskopisch diagnostiziert werden, was eine kurative Therapie erschwert. Nur eine effiziente frühzeitige Identifizierung von Risikopatienten mit Barrett-Ösophagus durch ein praktikables Screening-Programm auf Populationsebene wird zur Verbesserung der Prognose beitragen können.

show abstract

Sponge Sampling with Fluorescent In Situ Hybridization as a Screening Tool for the Early Detection of Esophageal Cancer

Abstract: Esophageal sponge cytology is a promising, safe, and tolerable method for collecting esophageal cell samples. However, our data suggest that p53 fluorescent in situ hybridization does not improve the sensitivity for detecting cancer in these samples.

Cited by 14 publications

References 21 publications

A Rapid Cytological Screening as pre-Endoscopy Screening for Early Esophageal Squamous Cell Lesions: A Prospective Pilot Study from a Chinese Academic Center

A Rapid Cytological Screening as pre-Endoscopy Screening for Early Esophageal Squamous Cell Lesions: A Prospective Pilot Study from a Chinese Academic Center

UroVysionTM Fluorescence In Situ Hybridization in Urological Cancers: A Narrative Review and Future Perspectives

Barrett-Screening: rationale, aktuelle Konzepte und Perspektiven

Contact Info

Product

Resources

About